Steminent Biotherapeutics Inc. (TPEX:7729)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
87.80
-1.00 (-1.13%)
At close: Feb 26, 2026
293.72%
Market Cap 5.85B
Revenue (ttm) n/a
Net Income (ttm) -156.75M
Shares Out 66.63M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 417,494
Average Volume 739,897
Open 90.00
Previous Close 88.80
Day's Range 85.20 - 90.00
52-Week Range 15.25 - 95.60
Beta n/a
RSI 63.88
Earnings Date Apr 22, 2026

About Steminent Biotherapeutics

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 47
Stock Exchange Taipei Exchange
Ticker Symbol 7729
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.